Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 11.31
ALXN's Cash to Debt is ranked higher than
72% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. ALXN: 11.31 )
ALXN' s 10-Year Cash to Debt Range
Min: 0.49   Max: 375
Current: 11.31

0.49
375
Equity to Asset 0.81
ALXN's Equity to Asset is ranked higher than
83% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ALXN: 0.81 )
ALXN' s 10-Year Equity to Asset Range
Min: 0.04   Max: 0.95
Current: 0.81

0.04
0.95
Interest Coverage 128.41
ALXN's Interest Coverage is ranked higher than
59% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 128.41 )
ALXN' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: 128.41

14.38
9999.99
F-Score: 7
Z-Score: 32.13
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 34.04
ALXN's Operating margin (%) is ranked higher than
96% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ALXN: 34.04 )
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21   Max: 35.65
Current: 34.04

-10370.21
35.65
Net-margin (%) 16.30
ALXN's Net-margin (%) is ranked higher than
91% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ALXN: 16.30 )
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86   Max: 76.31
Current: 16.3

-10220.86
76.31
ROE (%) 10.62
ALXN's ROE (%) is ranked higher than
90% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ALXN: 10.62 )
ALXN' s 10-Year ROE (%) Range
Min: -160.7   Max: 42.88
Current: 10.62

-160.7
42.88
ROA (%) 7.62
ALXN's ROA (%) is ranked higher than
91% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. ALXN: 7.62 )
ALXN' s 10-Year ROA (%) Range
Min: -43.83   Max: 37.53
Current: 7.62

-43.83
37.53
ROC (Joel Greenblatt) (%) 155.90
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. ALXN: 155.90 )
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1012.5   Max: 155.9
Current: 155.9

-1012.5
155.9
Revenue Growth (%) 38.70
ALXN's Revenue Growth (%) is ranked higher than
95% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ALXN: 38.70 )
ALXN' s 10-Year Revenue Growth (%) Range
Min: -70.5   Max: 498.1
Current: 38.7

-70.5
498.1
EBITDA Growth (%) 46.50
ALXN's EBITDA Growth (%) is ranked higher than
97% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ALXN: 46.50 )
ALXN' s 10-Year EBITDA Growth (%) Range
Min: -10.1   Max: 72.8
Current: 46.5

-10.1
72.8
EPS Growth (%) 34.70
ALXN's EPS Growth (%) is ranked higher than
95% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. ALXN: 34.70 )
ALXN' s 10-Year EPS Growth (%) Range
Min: -15.3   Max: 77.3
Current: 34.7

-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALXN Guru Trades in Q3 2013

Eric Mindich 300,000 sh (New)
Pioneer Investments 84,977 sh (+178.61%)
Steven Cohen 201,270 sh (+125.13%)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Frank Sands 7,540,405 sh (-10.5%)
Andreas Halvorsen 3,454,640 sh (-37.7%)
» More
Q4 2013

ALXN Guru Trades in Q4 2013

Eric Mindich Sold Out
Frank Sands 7,370,601 sh (-2.25%)
Andreas Halvorsen 2,877,008 sh (-16.72%)
Pioneer Investments 30,500 sh (-64.11%)
Steven Cohen 67,536 sh (-66.45%)
» More
Q1 2014

ALXN Guru Trades in Q1 2014

Ron Baron 10,218 sh (New)
Paul Tudor Jones 5,725 sh (New)
Ray Dalio 50,371 sh (New)
Joel Greenblatt 5,026 sh (New)
John Burbank 1,318 sh (New)
Pioneer Investments 31,453 sh (+3.12%)
Frank Sands 5,268,418 sh (-28.52%)
Steven Cohen 45,697 sh (-32.34%)
Andreas Halvorsen 1,836,658 sh (-36.16%)
» More
Q2 2014

ALXN Guru Trades in Q2 2014

Jim Simons 245,552 sh (New)
Joel Greenblatt 17,094 sh (+240.11%)
Andreas Halvorsen 2,006,092 sh (+9.23%)
Pioneer Investments 31,934 sh (+1.53%)
Frank Sands 5,279,782 sh (+0.22%)
Steven Cohen 11,700 sh (unchged)
John Burbank Sold Out
Ron Baron 10,145 sh (-0.71%)
Ray Dalio 26,332 sh (-47.72%)
Paul Tudor Jones 1,326 sh (-76.84%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ray Dalio 2014-06-30 Reduce -47.72%0.03%$139.61 - $170.2 $ 172.279%26332
Joel Greenblatt 2014-06-30 Add 240.11%0.02%$139.61 - $170.2 $ 172.279%17094
John Burbank 2014-06-30 Sold Out 0.01%$139.61 - $170.2 $ 172.279%0
Frank Sands 2014-03-31 Reduce -28.52%0.74%$129.82 - $183.89 $ 172.279%5268418
Ray Dalio 2014-03-31 New Buy0.06%$129.82 - $183.89 $ 172.279%50371
Ron Baron 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 172.279%10218
John Burbank 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 172.279%1318
Joel Greenblatt 2014-03-31 New Buy0.01%$129.82 - $183.89 $ 172.279%5026
Frank Sands 2013-09-30 Reduce -10.5%0.27%$94.34 - $117.28 $ 172.2757%7540405
Frank Sands 2013-03-31 Add 4.23%0.11%$83.39 - $102.57 $ 172.2785%8420336
Joel Greenblatt 2013-03-31 Sold Out 0.07%$83.39 - $102.57 $ 172.2785%0
Joel Greenblatt 2012-12-31 New Buy0.07%$87.97 - $118.15 $ 172.2775%12977
Frank Sands 2012-06-30 Add 6.43%0.27%$83.74 - $98.82 $ 172.2789%9739804
George Soros 2012-06-30 Sold Out 0.07%$83.74 - $98.82 $ 172.2789%0
George Soros 2012-03-31 New Buy0.07%$70.29 - $94.31 $ 172.27127%50000
Joel Greenblatt 2011-09-30 Sold Out 0.0882%$47.81 - $66.99 $ 172.27207%0
Joel Greenblatt 2011-06-30 New Buy0.09%$44.61 - $52.195 $ 172.27260%13417
George Soros 2011-06-30 Sold Out $44.61 - $52.195 $ 172.27260%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

Alexion CEO Receives Nearly $17 Million for Sale of Company Stock
The CEO of Alexion Pharmaceuticals Inc (ALXN), Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million. At a price of $160.71 per share, the sale of 105,000 shares of company stock brought $16,874,551. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 84.80
ALXN's P/E(ttm) is ranked higher than
84% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 84.80 )
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92   Max: 1113.68
Current: 84.8

13.92
1113.68
P/B 11.60
ALXN's P/B is ranked lower than
52% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. ALXN: 11.60 )
ALXN' s 10-Year P/B Range
Min: 1.73   Max: 32.18
Current: 11.6

1.73
32.18
P/S 17.70
ALXN's P/S is ranked higher than
62% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 19.49 vs. ALXN: 17.70 )
ALXN' s 10-Year P/S Range
Min: 9.66   Max: 1135
Current: 17.7

9.66
1135
PFCF 96.60
ALXN's PFCF is ranked higher than
87% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 96.60 )
ALXN' s 10-Year PFCF Range
Min: 40   Max: 99999999.99
Current: 96.6

40
99999999.99
EV-to-EBIT 45.85
ALXN's EV-to-EBIT is ranked higher than
88% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 45.85 )
ALXN' s 10-Year EV-to-EBIT Range
Min: 33   Max: 893.9
Current: 45.85

33
893.9
PEG 1.63
ALXN's PEG is ranked higher than
98% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 1.63 )
ALXN' s 10-Year PEG Range
Min: 0.68   Max: 2.63
Current: 1.63

0.68
2.63
Shiller P/E 130.30
ALXN's Shiller P/E is ranked higher than
89% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 130.30 )
ALXN' s 10-Year Shiller P/E Range
Min: 98.32   Max: 655.33
Current: 130.3

98.32
655.33
Current Ratio 5.61
ALXN's Current Ratio is ranked higher than
79% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. ALXN: 5.61 )
ALXN' s 10-Year Current Ratio Range
Min: 1.38   Max: 52.92
Current: 5.61

1.38
52.92
Quick Ratio 5.26
ALXN's Quick Ratio is ranked higher than
79% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. ALXN: 5.26 )
ALXN' s 10-Year Quick Ratio Range
Min: 1.38   Max: 52.92
Current: 5.26

1.38
52.92

Valuation & Return

vs
industry
vs
history
Price/Net Cash 36.30
ALXN's Price/Net Cash is ranked higher than
80% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. ALXN: 36.30 )
ALXN' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 205.55
Current: 36.3

1.37
205.55
Price/Net Current Asset Value 25.20
ALXN's Price/Net Current Asset Value is ranked higher than
79% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. ALXN: 25.20 )
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.37   Max: 470.75
Current: 25.2

1.37
470.75
Price/Tangible Book 16.50
ALXN's Price/Tangible Book is ranked higher than
66% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. ALXN: 16.50 )
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.15   Max: 82.09
Current: 16.5

1.15
82.09
Price/DCF (Projected) 6.10
ALXN's Price/DCF (Projected) is ranked higher than
91% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 6.10 )
ALXN' s 10-Year Price/DCF (Projected) Range
Min: 4.42   Max: 182.82
Current: 6.1

4.42
182.82
Price/Median PS Value 1.00
ALXN's Price/Median PS Value is ranked higher than
84% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. ALXN: 1.00 )
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 49.19
Current: 1

0.35
49.19
Price/Peter Lynch Fair Value 3.40
ALXN's Price/Peter Lynch Fair Value is ranked higher than
96% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 3.40 )
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 4.22
Current: 3.4

0.56
4.22
Price/Graham Number 7.80
ALXN's Price/Graham Number is ranked higher than
87% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 7.80 )
ALXN' s 10-Year Price/Graham Number Range
Min: 2.04   Max: 22.85
Current: 7.8

2.04
22.85
Earnings Yield (Greenblatt) 2.20
ALXN's Earnings Yield (Greenblatt) is ranked higher than
53% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALXN: 2.20 )
ALXN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: 2.2

0.1
3
Forward Rate of Return (Yacktman) 53.56
ALXN's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. ALXN: 53.56 )
ALXN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.1   Max: 75.3
Current: 53.56

-7.1
75.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany
Alexion Pharmaceuticals, Inc. is a Delaware based company incorporated in 1992 is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, transplant rejection, neurology and ophthalmology. Soliris is a humanized monoclonal antibody that blocks terminal complement activity at the doses currently prescribed. Soliris was approved for the treatment of PNH by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) in 2007 and by Japan's Ministry of Health, Labour and Welfare (MHLW) in 2010, and has been approved in several other territories. The Company competes with large pharmaceutical companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
fv 107 Apr 01 2013 
Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM Sep 03 2012 
Weekly Top Insider Sells: GOOG, YHOO, ALXN, and CTL Jun 04 2012 


More From Other Websites
Alexion's Soliris Manufacturing Facility Fails to Please FDA Aug 27 2014
3 Drugs Stocks Dragging The Industry Down Aug 27 2014
Rising Short Interest in Biotech Stocks Aug 27 2014
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As Aug 27 2014
Alexion is Tagged by the FDA for Production Problems -- Again Aug 26 2014
Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft... Aug 25 2014
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Aug 25 2014
Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft... Aug 25 2014
Roche to buy U.S. biotech firm InterMune for $8.3 billion Aug 25 2014
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Aug 20 2014
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins Aug 18 2014
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014
[video] Red hot biotech stocks Aug 14 2014
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the... Aug 14 2014
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the... Aug 13 2014
GW Pharma, Insys Face Off In Cannabis Drug Space Aug 08 2014
Today's Stocks Driving Success For The Health Care Sector Aug 08 2014
Wall Street Transcript Interview with Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics... Aug 08 2014
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Aug 07 2014
Politicians Shouldn't Question Drug Costs But Rather Their Value. Lessons From Soliris And Sovaldi. Aug 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK